Rezolute Inc (RZLT)

Currency in USD
2.165
-0.195(-8.26%)
Closed·
2.130-0.035(-1.62%)
·
RZLT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.1232.430
52 wk Range
1.07011.457
Key Statistics
Prev. Close
2.36
Open
2.37
Day's Range
2.123-2.43
52 wk Range
1.07-11.457
Volume
4.06M
Average Vol. (3m)
5.86M
1-Year Change
-58.68%
Book Value / Share
1.62
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RZLT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.125
Upside
+90.53%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Rezolute Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Rezolute Inc Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Rezolute Inc SWOT Analysis


Strategic Advantages
Discover the benefits of Rezolute's Orphan Drug Designation for ersodetug, including tax credits, fee exemptions, and potential market exclusivity
Market Potential
Learn how Rezolute's stock surged 27.65% on positive trial news, with analyst price targets ranging from $9 to $15, suggesting significant upside potential
Financial Strength
Delve into Rezolute's robust financial position, boasting $105 million in cash and a current ratio of 8.43, providing ample runway for drug development
Clinical Milestones
Explore Rezolute's progress in Phase 3 trials for ersodetug, targeting congenital and tumor-induced hyperinsulinism, with key interim results expected soon
Read full SWOT analysis

Compare RZLT to Peers and Sector

Metrics to compare
RZLT
Peers
Sector
Relationship
P/E Ratio
−2.6x−5.8x−0.6x
PEG Ratio
−0.100.080.00
Price / Book
1.4x4.1x2.6x
Price / LTM Sales
-357.6x3.2x
Upside (Analyst Target)
107.9%45.9%43.5%
Fair Value Upside
Unlock−3.6%5.7%Unlock

Analyst Ratings

6 Buy
4 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.125
(+90.53% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Guggenheim
Buy6.00+177.14%15.00MaintainDec 12, 2025
H.C. Wainwright
Buy5.00+130.95%14.00MaintainDec 12, 2025
Craig-Hallum
Hold2.00-7.62%-DowngradeDec 11, 2025
Jones Trading
Buy6.00+177.14%14.00MaintainDec 11, 2025
BTIG
Buy5.00+130.95%17.00MaintainDec 11, 2025

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-0.18 / -0.22
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

RZLT Income Statement

People Also Watch

275.24
SNDK
+15.95%
38.20
CORT
+9.77%
42.700
IREN
+13.05%
11.020
ONDS
+12.91%
14.15
USAR
+18.91%

FAQ

What Is the Rezolute (RZLT) Stock Price Today?

The Rezolute stock price today is 2.165

What Stock Exchange Does Rezolute Trade On?

Rezolute is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Rezolute?

The stock symbol for Rezolute is "RZLT."

What Is the Rezolute Market Cap?

As of today, Rezolute market cap is 200.76M.

What Is Rezolute's Earnings Per Share (TTM)?

The Rezolute EPS (TTM) is -0.92.

When Is the Next Rezolute Earnings Date?

Rezolute will release its next earnings report on Feb 11, 2026.

From a Technical Analysis Perspective, Is RZLT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Rezolute Stock Split?

Rezolute has split 3 times.

How Many Employees Does Rezolute Have?

Rezolute has 75 employees.

What is the current trading status of Rezolute (RZLT)?

As of Jan 04, 2026, Rezolute (RZLT) is trading at a price of 2.165, with a previous close of 2.360. The stock has fluctuated within a day range of 2.123 to 2.430, while its 52-week range spans from 1.070 to 11.457.

What Is Rezolute (RZLT) Price Target According to Analysts?

The average 12-month price target for Rezolute is USD4.125, with a high estimate of USD6 and a low estimate of USD1. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +90.53% Upside potential.

What Is the RZLT Premarket Price?

RZLT's last pre-market stock price is 2.380. The pre-market share volume is 63,220.000, and the stock has decreased by 0.020, or 0.850%.

What Is the RZLT After Hours Price?

RZLT's last after hours stock price is 2.130, the stock has decreased by -0.035, or -1.620%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.